Consensus Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-11-06 EST			5-day change	1st Jan Change
166.89 ^USD	-0.41%		-2.22%	+35.97%

11-06	Gilead Sciences Says Twice-Yearly Lenacapavir Shows Higher PrEP Persistence in Phase 2 Trial	MT
11-05	Maxim Adjusts Price Target on Gilead Sciences to $200 From $165	MT

Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

7df5256c65e809fac94dde0d67.2VM2AIJsRxMOx6BCeCKaKW9a2PAyAMfJ6jUHzGIOWcU.kStgUNEuJWY6rJkoIXLXT1YsibxXcLajuQMyphBGA5L0BGduwz0BSniGmA~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

11-05	Maxim Adjusts Price Target on Gilead Sciences to $200 From $165	MT
11-04	DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167	MT
10-30	Gilead's HIV Franchise Supports Growth Outlook, RBC Says	MT
10-30	UBS Adjusts Gilead Sciences Price Target to $195 From $175, Maintains Buy Rating	MT
10-30	Needham Adjusts Price Target on Gilead Sciences to $200 From $170	MT
10-30	Leerink Partners Adjusts Price Target on Gilead Sciences to $145 From $129	MT
10-30	RBC Raises Price Target on Gilead Sciences to $131 From $126, Keeps Sector Perform Rating	MT
10-29	Not All AI Billions Are Equal
10-21	Gilead's Biktarvy Pricing Impact Likely Manageable, RBC Says	MT
10-15	Goldman Sachs Adjusts Price Target on Gilead Sciences to $142 From $135	MT
10-12	Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says	MT
10-12	BofA Securities Adjusts Gilead Sciences Price Target to $168 From $162, Maintains Buy Rating	MT
10-08	RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating	MT
10-07	Morgan Stanley Adjusts Price Target on Gilead Sciences to $163 From $165	MT
10-07	JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160	MT
10-02	Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says	MT
09-10	HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating	MT
08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
08-05	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
08-05	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
08-04	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says	MT
07-28	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
07-23	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
07-21	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GILEAD SCIENCES, INC.					+3.36%
	ELI LILLY AND COMPANY					+6.51%
	JOHNSON & JOHNSON					+1.15%
	ABBVIE INC.					+5.32%
	ROCHE HOLDING AG					+1.08%
	MERCK & CO., INC.					+10.08%
	NOVARTIS AG					-6.85%
	ASTRAZENECA PLC					+15.35%
	AMGEN INC.					-9.12%
	NOVO NORDISK A/S					+10.95%
	Average					+3.78%
	Weighted average by Cap.					+4.16%